SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549


                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934



Date of Report: July 23, 2003

                        --------------------------------

                              HYCOR BIOMEDICAL INC.

             (Exact name of registrant as specified in its charter)

                                     0-11647
                            (Commission File Number)


            Delaware                                        58-1437178
 (State or other jurisdiction of                         (I.R.S. Employer
 incorporation or organization)                        Identification No.)



                                7272 Chapman Ave
                         Garden Grove, California 92841
             (Address of principal executive offices, with zip code)

                                 (714) 933-3000
              (Registrant's telephone number, including area code)











Item 7.  FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

     (c)  EXHIBITS

          99.1  Press Release dated July 23, 2003

Item 9.  REGULATION FD DISCLOSURE

         On July 23, 2003 Hycor Biomedical Inc issued a press release reporting
         its financial results for the quarter ended June 30, 2003. A copy of
         the press release is attached hereto as Exhibit 99.1 and is
         incorporated herein by reference. This information is being furnished
         under both Item 9 (Regulation FD Disclosure) and Item 12 (Results of
         Operations and Financial Condition) of Form 8-K and is included under
         this Item 9 in accordance with SEC Release No. 33-8126. This
         information shall not be deemed "filed" for purposes of Section 18 of
         the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
         or incorporated by reference in any filing under the Securities Act of
         1933, as amended, or the Exchange Act, except as shall be expressly set
         forth by specific reference in such a filing.



                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                   Hycor Biomedical Inc.

Date:    July 23, 2003             By:   /s/ Reg Jones
                                      ------------------------------------------
                                   Reg Jones
                                   Executive Vice President and Chief Financial
                                   Officer (Principal Financial Officer)










                                INDEX TO EXHIBITS


Exhibit Number                                       Description
- --------------                                       -----------
         99.1                             Press Release dated July 23, 2003